Renin-angiotensin system and stroke
- 9 August 2008
- journal article
- review article
- Published by Springer Nature in Neurological Sciences
- Vol. 29 (2) , 277-278
Abstract
The renin-angiotensin system (RAS) is a major regulatory system of cardiovascular and renal function. Many new aspects of this system have been revealed in recent years, leading to new therapeutic approaches. It's well known that RAS blocking agents have potent antiatherosclerotic effects, which are mediated by their antihypertensive, anti-inflammatory, antiproliferative, and oxidative stress lowering properties. Inhibitors of RAS are now first-line treatments for hypertensive target organ damage. Their effects are greater than expected by their ability to lower blood pressure. Angiotensin receptor blockers reduce the frequency of atrial fibrillation and stroke, are also able to prevent cardiovascular and renal events in diabetic patients. Thus, blockade of RAS represents one of the most important strategies in order to reduce cardiovascular risk.Keywords
This publication has 6 references indexed in Scilit:
- Renin-angiotensin system and cardiovascular riskThe Lancet, 2007
- Angiotensin receptor blockers and cerebral protection in strokeJournal Of Hypertension, 2006
- Circulating Endothelial Progenitor Cells and Cardiovascular OutcomesNew England Journal of Medicine, 2005
- Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for TherapyStroke, 2002
- The renin angiotensin system as a risk factor for coronary artery diseaseCurrent Atherosclerosis Reports, 2001
- Angiotensin II in central nervous system physiologyRegulatory Peptides, 1998